Your browser doesn't support javascript.
loading
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert, Lucy; Oaknin, Ana; Matulonis, Ursula A; Mantia-Smaldone, Gina M; Lim, Peter C; Castro, Cesar M; Provencher, Diane; Memarzadeh, Sanaz; Method, Michael; Wang, Jiuzhou; Moore, Kathleen N; O'Malley, David M.
Affiliation
  • Gilbert L; McGill University Health Center-Research Institute, Montreal, Canada. Electronic address: lucy.gilbert@mcgill.ca.
  • Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: aoaknin@vhio.net.
  • Matulonis UA; Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: Ursula_Matulonis@dfci.harvard.edu.
  • Mantia-Smaldone GM; Fox Chase Cancer Center, Philadelphia, PA, United States. Electronic address: gina.mantia-smaldone@fccc.edu.
  • Lim PC; The Center of Hope Renown Regional Medical Center, Reno, NV, United States. Electronic address: pclim@cohreno.com.
  • Castro CM; Massachusetts General Hospital, Boston, MA, United States. Electronic address: cmcastro@mgh.harvard.edu.
  • Provencher D; Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada. Electronic address: diane.provencher.chum@ssss.gouv.qc.ca.
  • Memarzadeh S; Ronald Reagan UCLA Medical Center, Los Angeles, CA, United States. Electronic address: smemarzadeh@mednet.ucla.edu.
  • Method M; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: michael.method@immunogen.com.
  • Wang J; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: joe.wang@immunogen.com.
  • Moore KN; Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address: kathleen-moore@ouhsc.edu.
  • O'Malley DM; The Ohio State University, James Comprehensive Cancer Center, Columbus, OH, United States. Electronic address: David.O'Malley@osumc.edu.
Gynecol Oncol ; 170: 241-247, 2023 03.
Article in En | MEDLINE | ID: mdl-36736157
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Immunoconjugates / Antineoplastic Agents Limits: Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Immunoconjugates / Antineoplastic Agents Limits: Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2023 Document type: Article Country of publication: